Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.
Thomas Powles, MBBS, MCRP, MD
Advertisement
Articles by Thomas Powles, MBBS, MCRP, MD
The Q-TWiST analysis from the LITESPARK-005 trial showed statistically significant improvement of belzutifan over everolimus in patients with clear cell RCC.
Results from a Q-TWiST analysis of the LITESPARK-005 trial showed a trend favoring belzutifan over everolimus for patients with clear cell RCC.
Kidney cancer experts explain how they dose lenvatinib in advanced renal cell carcinoma treatment to mitigate toxicities.
The expert from Barts Cancer Centre in London discusses future directions for avelumab and the rapidly advancing field of urothelial cancer.
Advertisement
Latest Updated Articles
Q-TWiST Analysis Assesses Progression/Toxicity of Belzutifan Vs Everolimus in ccRCCPublished: July 18th 2025 | Updated:
Key Advances Across Kidney Cancer Research and Management at KCRS 2025Published: July 28th 2025 | Updated:
- Q-TWiST Analysis Builds on LITESPARK-005 Efficacy of Belzutifan in ccRCC
Published: July 19th 2025 | Updated:
Thomas Powles, MD, PhD on Next Steps for Avelumab and the Future of Treatment for Urothelial CancerPublished: June 3rd 2020 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma
2
HDP-101 Receives FDA Fast Track Designation in Multiple Myeloma
3
FDA Grants Priority Review to Enfortumab Vedotin Combo in MIBC Subset
4
Exa-Cel Improved HRQOL for in Transfusion-Dependent β-Thalassemia
5
